BIO-MH-Early Biomarkers in Premanifest Huntington's Disease Gene Carriers
Recruiting
This study is a prospective, single-center, case-control pilot study.
The primary goal of this study is to look at the function of superior colliculus(SC). This midbrain structure is involved in the integration of visual stimuli, in the generation of oriented eye movements and attention tasks.
Functional MRI(fMRI) will be used to measure this and compare premanifest HD gene carriers (PMGC) and healthy subjects (HS). Does the fMRI detect early biomarkers of the disease in genetic carriers?
The other part of the study is to asses gait(a person’s manner of walking) using a virtual reality device: Can this detect early biomarkers of the disease in genetic carriers?
This an open label.
Phase: not applicable
Subtype: Interventional Biomarker
Primary Purpose: Diagnostic
Primary Intervention: brain functional MRI
Ages Eligible
for Study:
18 Years to 70 Years
(Adult, Older Adult )
Sexes Eligible
for Study:
All
Accepts Healthy Volunteers:
Yes
- 1. For presymptomatic genetic carriers of Huntington(PMGC): HD diagnosis confirmed by genetic testing (CAG triplets ≥36 in HTT gene); Unified Huntington Disease Rating Scale19 Total Motor Score (UHDRS-TMS) ≤ 5; age 18-70 years old. 2.
- For Healthy Controls(HC): normal neurological examination; age 18-70 years old.
- Main exclusion criteria for both PMGC and HC will be: major ophthalmologic and psychiatric active diseases; cognitive impairment (Montreal Cognitive Assessment, MoCA score < 25/30); gait issues related to non-neurological conditions; contraindications to brain MRI.
LOCATION
FRANCE
TRIAL SITE:
Grenoble University Hospital
Address: Grenoble, France
CONTACT:Sara Meoni, MD, PhD
Email: smeoni@chu-grenoble.fr
